MORA Cure is a prescription digital therapeutic for patients with Patellofemoral Pain (PFP), designed to deliver an 8‑week program that combines structured rehabilitation exercises with cognitive behavioral therapy (CBT).

Product overview and role
MORA Cure is a physician‑prescribed digital therapeutic that has obtained manufacturing approval from the Korean MFDS as a Class II digital therapeutic device (product code C3ABXA1, manufacturing license D‑Jein‑25‑4064) and has been designated as an Innovative Medical Device (No. 101) for the indication of patellofemoral pain. It consists of a patient‑facing smartphone application and a clinician‑facing web platform, delivering an 8‑week personalized rehabilitation and pain/behavior management program to patients while enabling clinicians to monitor treatment adherence and clinical progress in real time.

Digital treatment framework for PFP
Patellofemoral pain is a representative musculoskeletal pain condition in which anterior knee or peripatellar pain is exacerbated during everyday activities such as stair climbing, squatting, prolonged sitting, and running. Its pathophysiology is multifactorial, involving lower‑limb strength, alignment, movement control, activity level, pain perception, and psychological/behavioral factors; excessive pain‑related worry, fear of movement, activity avoidance, and low self‑efficacy can reduce treatment adherence, delay functional recovery, and contribute to symptom chronicity, making it difficult to manage adequately through conventional in‑clinic care alone.

MORA Cure is designed to address these unmet needs by providing a structured, prescription‑based digital treatment pathway: Key features: Exercise therapy + CBT + Vision AI
Personalized rehabilitation exercise program
MORA Cure delivers an evidence‑based rehabilitation exercise program that targets lower‑limb strengthening, movement control, and functional recovery specific to patellofemoral pain.

Program intensity and content are progressively tailored based on each patient’s baseline status and ongoing performance, with a focus on restoring function in symptom‑provoking activities such as stair ambulation and sit‑to‑stand.

CBT‑based pain and behavior management
The solution provides CBT‑informed content aimed at pain education, restructuring maladaptive pain‑related thoughts, reducing fear of movement, decreasing activity avoidance, gradually increasing activity levels, and building sustainable self‑management behaviors.

Beyond simple exercise instructions, MORA Cure is designed to help patients better understand their pain, reduce fear and avoidance patterns, and actively engage in the treatment process.

Vision AI‑based quantitative functional assessment
MORA Cure leverages EverEx’s proprietary Vision AI pose‑estimation technology to analyze smartphone videos, estimate key joint positions, and quantify biomechanical metrics such as joint angles, alignment, and range of motion.

The system uses an in‑house, medically curated model based on 24 musculoskeletal joint points, providing quantitative functional data that support personalized exercise prescription and objective evaluation of pre‑ and post‑treatment functional changes.

Clinical evidence and efficacy
MORA Cure has been evaluated in a prospective, randomized, confirmatory clinical trial involving 216 patients with patellofemoral pain across 10 Korean medical centers. On the strength of these results, MORA Cure is recognized as an evidence‑based musculoskeletal digital therapeutic that has demonstrated concurrent improvements in: Positioning and health‑system integration
Building on its regulatory approvals and clinical data, MORA Cure is being developed as a reference model for musculoskeletal digital therapeutics in Korea, with the following system‑level objectives: To this end, EverEx and a consortium of four tertiary hospitals (CAU Hospital, Inha University Hospital, Hanyang University Guri Hospital, and Seoul St. Mary’s Hospital) are conducting multi‑center prospective real‑world data (RWD) studies and retrospective analyses to build robust real‑world evidence, economic data, and user‑acceptance profiles.

Future expansion: platform extension to LBP and RCR
As outlined in the business plan, the MORA platform is architected to extend beyond PFP to other high‑burden musculoskeletal pain and rehabilitation indications, notably Low Back Pain (LBP) and Rotator Cuff‑related (RCR) shoulder conditions.

Although their pathologies and typical age distributions differ, PFP, early knee osteoarthritis, LBP, and RCR share common rehabilitation requirements: functional impairment driven by pain, difficulty with key functional movements (such as stair climbing or overhead tasks), the need to improve lower‑limb, trunk, and shoulder girdle strength and motor control, and the necessity of long‑term exercise therapy and adherence management.

EverEx’s mid‑ to long‑term strategy is to leverage the real‑world evidence, economic analyses, and clinical implementation experience obtained from the PFP indication to sequentially design and develop additional prescription digital therapeutics for: Accordingly, MORA Cure for PFP is positioned not merely as a single‑indication product, but as the first core module of a broader musculoskeletal digital therapeutic platform that can be expanded to LBP, RCR, and other MSK conditions over time.